AI-Designed Drug Might Slow Biological Aging — Live Feedhttps://www.live-feeds.com/feed/ai-designed-drug-might-slow-biological-agingContinuously updated, source-cited coverage. AI-Designed Drug Shows Early Signs of Slowing Human Aginghttps://www.live-feeds.com/feed/ai-designed-drug-might-slow-biological-aginghttps://www.live-feeds.com/feed/ai-designed-drug-might-slow-biological-aging#u66146Sat, 12 Sep 2026 10:55:07 +0000An artificial intelligence-designed medication originally intended to treat a serious lung disease is displaying early signs of reducing signs of human aging. Insilico Medicine advanced its primary clinical program to Phase III trials, dosing the first patient in the GENESIS-IPF-3 study on September 9, 2026. While the primary target remains specific pulmonary issues, researchers are utilizing proteomic aging clocks in Phase 2a trials to evaluate potential geroprotective effects. Separate predictive biology initiatives by companies like Astromech are also leveraging evolutionary history models AI-Designed Lung Disease Drug Shows Potential to Slow Biological Aginghttps://www.live-feeds.com/feed/ai-designed-drug-might-slow-biological-aginghttps://www.live-feeds.com/feed/ai-designed-drug-might-slow-biological-aging#u64195Thu, 10 Sep 2026 18:56:45 +0000Insilico Medicine is testing a generative AI-driven drug that may slow biological aging. Originally developed to treat lung disease, early data suggests the medication provides a geroprotective effect. The company has progressed its primary clinical program to Phase III trials, dosing the first patient in the GENESIS-IPF-3 study on September 9, 2026. While the drug targets specific pulmonary issues, researchers are utilizing proteomic aging clocks in Phase 2a trials to assess its impact on the aging process.Why it mattersGenerative AI is being used to discover novel drug candidates more effici